Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07669415 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669415 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669415 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669740 Albumin-Bound Paclitaxel Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669740 Albumin-Bound Paclitaxel Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669740 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669363 Haloperidol Cervical Intraepithelial Neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669363 Haloperidol Cervical Intraepithelial Neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669363 clinical trial report covering Haloperidol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07668323 Alteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07668323 Alteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07668323 clinical trial report covering Alteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07675811 REGN-1908-1909 Cat allergy (disorder) Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07675811 REGN-1908-1909 Cat allergy (disorder) Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07675811 clinical trial report covering REGN-1908-1909, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07676331 Letrozole Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07676331 Letrozole Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07676331 clinical trial report covering Letrozole, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07674745 Rituximab Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07674745 Rituximab Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07674745 clinical trial report covering Rituximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262449 Eloralintide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262449 Eloralintide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262449 clinical trial report covering Eloralintide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07679399 Durvalumab Gallbladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07679399 Durvalumab Gallbladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07679399 clinical trial report covering Durvalumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07679997 Trilaciclib Dihydrochloride Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07679997 Trilaciclib Dihydrochloride Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07679997 clinical trial report covering Trilaciclib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07678775 Ribitol Muscular Dystrophy, Limb-Girdle, Type 2I Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07678775 Ribitol Muscular Dystrophy, Limb-Girdle, Type 2I Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07678775 clinical trial report covering Ribitol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07677813 Zuberitamab Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07677813 Zuberitamab Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07677813 clinical trial report covering Zuberitamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →